The DC vaccine transduced with wild-type p53 was tested in small cell lung cancer patients without previous positive p53 responses and only 20% of them developed p53-specific responses, with no significant variations in the levels of granzyme B-positive CD8 T cells and MDSCs (128). This evidence concerns the gene TP53 and small cell lung carcinoma.